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Objective. To identify national outcomes of thoracic endovascular aortic repair (TEVAR) for type B aortic dissections (TBADs).
Methods. The Nationwide Inpatient Sample database was examined from 2005 to 2008 using ICD-9 codes to identify patients with
TBAD who underwent TEVAR or open surgical repair. We constructed separate propensity models for emergently and electively
admittedpatientsandcalculatedmortalityandcomplicationratesforpropensityscore-matchedcohortsofTEVARandopenrepair
patients. Results. In-hospital mortality was signiﬁcantly higher following open repair than TEVAR (17.5% versus 10.8%, P = .045)
in emergently admitted TBAD. There was no in-hospital mortality diﬀerence between open repair and TEVAR (5.6% versus 3.3%,
P = .464) for elective admissions. Hospitals performing thirty or more TEVAR procedures annually had lower mortality for
emergent TBAD than hospitals with fewer than thirty procedures. Conclusions. TEVAR produces better in-hospital outcomes in
emergent TBAD than open repair, but further longitudinal analysis is required.
1.Background
Aorticdissectionisararecondition,withannualincidenceof
three to eight cases/100,000 people [1–3], which is associated
with high morbidity and mortality. Type A aortic dissections
a r ev i e w e da ss u r g i c a le m e r g e n c i e s ,b u tt h et r e a t m e n to ft yp e
B aortic dissections (TBADs), which account for about one-
third of total aortic dissections [4], is more variable. Acute
type B dissections that are complicated by visceral or limb
ischemia, aortic rupture, refractory pain, or rapidly expand-
ing dissection also require surgical intervention [5]. In the
absence of such complications, which is the case for seventy
percent of patients with acute type B dissection [6], medical
therapy with antihypertensives has been the standard of care.
In2005,theUSFoodandDrugAdministrationapproved
thoracic endovascular aortic repair (TEVAR) for the repair
of thoracic aortic aneurysms [7], and surgeons have increas-
ingly been using TEVAR oﬀ-label to treat TBAD. The high
mortality rates associated with traditional open thoraco-
tomy surgical repair of complicated TBAD have driven
the increased adoption of the less invasive TEVAR in
complicated TBAD. The possibility that TEVAR can facilitate
better remodeling of the aorta than medical therapy and
avert late aortic rupture has stimulated its use in treating
uncomplicatedTBADpatients,whotraditionallywouldhave
received medical therapy alone [8, 9].
Most studies on the outcomes of TEVAR have been
small, single center studies [10, 11], or meta-analyses with
potential selection biases [5, 12], but Sachs et al. [13]w e r e
the ﬁrst to conduct a large population study utilizing the
Nationwide Inpatient Sample which compared the outcomes
of treatment with TEVAR versus open surgery in TBAD
patients. Our study expands on the work done by Sachs et al.
[13], as we include an additional year of data (2008) and
utilize a propensity score matching approach that more
eﬀectively controls for diﬀerences between treatment groups
than standard multivariate analysis. Moreover, we examine
the relationship between volume and outcome of TEVAR
procedures.2 International Journal of Vascular Medicine
2.MaterialsandMethods
2.1. Data Sources and Study Population. We used the Nation-
wide Inpatient Sample (NIS) database to identify patients
with type B thoracic aortic dissections who underwent
surgical repair between 2005 and 2008. The NIS is the largest
all-payer inpatient care database and contains discharge data
from over eight million hospitalizations per year, which is
approximately twenty percent of all hospitalizations in the
United States.
International Classiﬁcation of Diseases, the 9th edition
(ICD-9) diagnosis codes were used to identify all patients
in the NIS with thoracic aortic dissections (441.01). Patients
with thoracic dissections treated surgically were separated
from those receiving medical therapy alone by using proce-
durecodesforendovascularstentgraftrepair(39.73)oropen
repair (38.34, 38.45). The ICD-9 procedure code for TEVAR
was introduced in September 2005, which limited our study
to the period from 2005 to 2008. Additionally, we excluded
all patients with diagnosis codes for aortic aneurysms (441.1
to 441.9), to better restrict the analysis to patients with acute
dissection. We isolated type B aortic dissections from type
A aortic dissections using criteria developed by Sachs et al.
[13], in which patients with procedure codes for cardioplegia
(39.63), valve repair (35.00–35.99), or operations on vessels
of the heart (36.00–36.99, 37.0, 37.2, 37.31–37.90, 37.93–
37.99), who were more likely to have type A dissections,
were excluded. We further stratiﬁed the patients with type B
dissections based on whether they were admitted emergently
or electively to the hospital.
The following patient demographics and hospital char-
acteristics were identiﬁed: age, gender, hospital bed size,
hospital teaching status, and annual volume of TEVAR
performed per hospital. The following comorbidities were
assessed: cardiac arrhythmias, chronic congestive heart fail-
ure (CHF), coronary artery disease, valvular heart disease,
chronic pulmonary disease, chronic renal failure, coagu-
lopathy, deﬁciency anemias, diabetes, hypertension, obesity,
neurological disorders, paralysis, and peripheral vascular
disease (Table 1).
2.2. Statistical Analysis. In order to control for imbalances
of patient characteristics and institutional characteristics
among the treatment groups that might inﬂuence treatment
outcome, we used a propensity scoring method to establish
matched cohorts. Separate models were created for emergent
and elective admissions. A propensity score, which was
assigned to each hospitalization, was based on a multivariate
logistic regression model that examined the impact of thirty
variables (patient demographics, comorbidities, and hospital
characteristics) on the likelihood of treatment assignment.
Patients with similar propensity scores in the two treatment
groups were matched using a 1-to-1 scheme without replace-
ment, using 8-to-1 digit match.
Outcomes were compared between propensity score-
matched cohorts of patients undergoing TEVAR and open
surgery. The primary outcomes measured were in-hospital
mortality, in-hospital complications, and length of stay
(LOS). Complications included acute renal failure, cardiac
complications, neurological complications, paraplegia, pos-
themorrhagic anemia, postoperative hemorrhage, pul-
monary complications, stroke, and thrombectomy/embolec-
tomy. The ICD-9 diagnosis codes used to code for comor-
bidities and complications are provided in Table 1.P a i r e d
t-test was used for comparisons of continuous variables
and the McNemar test for categorical variables in matched
cohorts. All statistical analyses were performed using SAS 9.2
software (SAS Institute Inc., Cary, NC).
3. Results
3.1. Baseline Demographics and Comorbidities. During the
period 2005–2008, 4752 emergently admitted patients with
TBAD were treated surgically: 3427 (72.1%) underwent
open repair, and 1325 (27.9%) underwent TEVAR (Table 2).
During this same period of time, 1247 electively admitted
patients with TBAD were treated surgically: 680 (54.5%)
underwent open repair, and 567 (45.5%) underwent TEVAR
(Table 3). Among those admitted emergently, TEVAR recip-
ients were signiﬁcantly more likely to have coronary artery
disease, chronic pulmonary disease, diabetes, peripheral
vascular disease and to be treated in hospitals with higher
TEVAR volume. In contrast, open repair patients had
higher rates of cardiac arrhythmia, valvular disease, and
coagulopathy (Table 2). Among electively admitted patients,
TEVAR recipients were older, had higher rates of diabetes,
hypertension, and were more likely to receive their care at
higher TEVAR volume hospitals. Open repair patients had
signiﬁcantly higher rates of valvular disease and coagulopa-
thy (Table 3).
3.2.Outcomes. Propensityscorematchingintheemergently-
admitted TBAD patients produced 991 matched pairs.
Demographic traits and comorbidities were balanced
between these matched cohorts (Table 2). The P value for
the Hosmer-Lemeshow goodness-of-ﬁt test of the propensity
score model was 0.605, and the c statistic was 0.828. In-
hospital mortality among emergently admitted patients was
signiﬁcantly higher among open repair recipients than in
TEVAR recipients (17.5% versus 10.8%, P = .045). Open
repair was associated with higher rates of acute renal failure
(27.3% versus 16.8%, P = .008), cardiac complications
(16.6%versus8.9%,P = .029), andposthemorrhagic anemia
(22.6% versus 12.1%, P = .006) (Table 4).
Propensity score matching in electively admitted TBAD
patients produced 282 matched pairs. Demographic charac-
teristicsandcomorbidconditionsweresimilarbetweenthese
two matched cohorts (Table 3). The P value for the Hosmer-
Lemeshow goodness-of-ﬁt was 0.137, and the c statistic was
0.858. In-hospital mortality was not signiﬁcantly diﬀerent
among recipients of TEVAR and open surgery (5.6% versus
3.3%, P = .464). Open repair recipients did have higher
rates of in-hospital complications such as acute renal failure
(13.0%versus1.7%,P = .021),cardiaccomplications(15.8%
versus 3.6%, P = .021), posthemorrhagic anemia (17.3%
versus 3.5%, P = .017), postoperative hemorrhage (19.1%International Journal of Vascular Medicine 3
Table 1: List of ICD-9 codes for comorbidities and complications.
(a)
Comorbidity ICD-9 code
Cardiac arrhythmia 426.0, 426.10, 426.11, 426.12, 426.13, 426.7, 426.9, 427.0, 427.1, 427.2, 427.3, 427.9, V45.0, V53.3
Chronic CHF 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.91, 404.13, 404.93, 425.4, 425.5, 425.7,
425.8, 425.9, 428.0, 428.1, 428.20, 428.22, 428.30, 428.32, 428.40, 428.42, 428.9
Coronary disease 412, 413, 414, 429.2
Valvular disease 093.2, 394, 395, 396, 397, 424, 746.3, 746.4, 746.5, 746.6, V42.2, V43.3
Cardiac comorbidities Any of the codes for cardiac arrhythmia, chronic CHF, coronary disease, or valvular disease
Chronic pulmonary disease 416, 417.9, 490, 491, 492, 493, 494, 495.0, 495.1, 495.2, 495.3, 495.4, 495.5, 495.6, 495.8, 495.9, 496,
500, 501, 502, 503, 504, 505, 506.0, 506.2, 506.4, 506.9, 508.1, 508.8, 508.9
Chronic renal failure 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13,404.92, 404.93, 585, 586, V42.0, V45.1,
V56.0–V56.2, V56.8
Coagulopathy 2860–2869, 287.1, 287.3–287.5, 289.81–289.82
Deﬁciency anemias 280.1–281.9, 285.21–285.29, 285.9
Diabetes 250
Hypertension 401.0, 401.1, 401.9, 402.00, 402.10, 402.90, 403.00, 403.10, 403.90, 404.00, 404.10, 404.90, 405.01,
405.09, 405.11, 405.19, 405.91, 405.99, 462.24, 642.00–642.04, 642.10, 642.70–642.94
Obesity 278.0, 278.00, 278.01, V85.30, V85.31, V85.32, V85.33, V85.34, V85.35, V85.36, V85.37, V85.38,
V85.39, V85.4, V85.54
Other neurological disorders
330.0–331.9, 332.0, 333.4, 333.5, 334.0–335.9, 333.71, 333.72, 333.79, 333.85, 333.94, 338.0, 340,
341.1–341.9, 345.00–345.11, 345.2–345.3, 345.40–345.91, 34700, 34701, 34710, 34711, 348.1,
348.3–348.39, 780.3, 780.39, 784.3
Paralysis 342.0–342.12, 342.9–344.9, 438.20–438.53
Peripheral vascular disease 440.0–440.9, 441.00–441.9, 442.0–442.9, 443.1–443.9, 444.21, 444.22, 449, 447.1, 557.1, 557.9, V43.4
(b)
Complication ICD-9 code
Acute renal failure 584
Cardiac complications
410.00, 410.01, 410.10, 410.11, 410.20, 410.21, 410.30, 410.31, 410.40, 410.41, 410.50, 410.51,
410.60, 410.61, 410.70, 410.71, 410.80, 410.81, 410.90, 410.91, 411.0, 411.1, 411.81, 411.89, 427.5,
428.21, 428.3, 428.31, 428.32, 428.41, 428.43, 997.1
Neurological complications 780.01 344.1 997.02 997.0 435 436, 437.1
Paraplegia 344.1
Posthemorrhagic anemia 285.1
Postoperative hemorrhage 998.1
Pulmonary complications 311, 312.9, 415.0, 415.11, 415.12, 415.19, 481, 482.0, 482.1, 482.2, 482.30, 482.31, 482.32, 482.39,
482.81, 482.82, 482.83, 482.84, 482.89, 482.9, 485, 486, 518.0, 518.4, 518.82, 518.84, 528.81, 997.3
Stroke 997.02
Thrombectomy or embolectomy 38.03, 38.04, 38.06, 38.08
versus 5.2%, P = .009), and pulmonary complications
(35.0% versus 16.2%, P = .034) (Table 5).
3.3. TEVAR Volume-Mortality Relationship. To determine
whether outcomes of TEVAR treatment for TBAD are related
to overall hospital experience with this procedure (i.e., for
aneurysms and dissection), we grouped hospitals by overall
TEVAR volume and compared in-hospital TBAD mortality
rates. We limited the analysis to TBAD patients admitted
emergently to help control for patient diﬀerences (Figure 1).
The cut-oﬀ volumes for the six TEVAR volume groups were
established so that each group would have a similar number
of emergently admitted TBAD patients treated with TEVAR.
The lowest volume group (1–4 TEVAR procedures/year)
has the highest mortality rate (13.4%). The highest volume
group (over 55 TEVAR procedures/year) has the lowest
mortality rate (2.9%). The TBAD mortality rate, which was
relatively uniform at lower volumes, declined steadily as4 International Journal of Vascular Medicine
Table 2: Baseline characteristics of emergently admitted patients undergoing open surgical repair or TEVAR for type B dissections from
2005 to 2008.
Variable Unmatched cohort Matched cohort
Open repair
(n = 3427)
TEVAR
(n = 1325)
P value Open repair
(n = 991)
TEVAR
(n = 991)
P value
Mean or % of patients Mean or % of patients
Female sex 37.2 38.9 0.642 35.5 40.4 0.309
Age
Mean age (years) 59.9 61.2 0.153 61.9 61.0 0.429
<60 yr 47.3 39.8 0.027 37.0 38.1 0.826
60–64 yr 10.5 12.9 0.302 12.2 12.8 0.868
65–69 yr 11.5 10.6 0.701 14.1 12.2 0.576
70–74 yr 9.9 11.9 0.393 13.0 13.5 0.890
75–79 yr 11.0 13.8 0.230 13.8 12.8 0.782
≥80 yr 9.8 11.1 0.511 9.9 10.7 0.751
Hospital bed size
Small 3.4 16.5 <0.001 5.5 7.2 0.550
Medium 14.9 12.0 0.446 13.6 15.4 0.683
Large 81.7 71.6 0.144 80.9 77.4 0.468
Teaching hospital 73.6 74.3 0.933 82.2 79.3 0.518
Mean annual TEVAR volume (n) 8.2 27.3 <0.001 15.1 15.4 0.894
Comorbid conditions
Cardiac comorbidities 54.9 39.9 <0.001 44.9 42.1 0.558
Cardiac arrhythmia 34.1 14.8 <0.001 15.3 16.8 0.648
Chronic CHF∗ 11.8 9.2 0.186 9.3 9.5 0.940
Coronary disease 10.1 17.5 0.004 19.4 17.0 0.556
Valvular disease 20.3 10.7 0.003 12.7 12.8 0.976
Chronic pulmonary disease 15.0 23.9 <0.001 25.3 24.0 0.755
Chronic renal failure 10.0 10.9 0.679 7.8 10.1 0.346
Coagulopathy 19.9 8.1 <0.001 9.0 10.3 0.666
Deﬁciency anemias 15.4 14.3 0.674 16.8 15.5 0.693
Diabetes 7.7 12.3 0.012 10.8 11.9 0.691
Hypertension 65.8 66.0 0.950 65.8 66.3 0.922
Obesity 7.1 4.6 0.142 3.9 4.4 0.782
Other neurological disorders 5.1 3.1 0.198 2.5 2.8 0.876
Paralysis 5.4 5.1 0.838 5.3 6.2 0.687
Peripheral vascular disease 14.9 32.6 <0.001 25.6 25.7 0.980
∗CHF: congestive heart failure.
hospital TEVAR volumes reached 30 per year. In fact the
TBAD in-hospital mortality rate for hospitals performing
less than 30 procedures per year was more than twice the rate
seen in hospitals that performed more than 30 per year (<30
= 11.3%, ≥30 = 4.8%; P = .047).
4. Discussion
We looked at TEVAR and open repair use for type B
aortic dissection over a four-year period and compared
outcomes. To control for selection bias we used a propensity
score model to create matched cohorts of patients for
the comparisons. Among patients treated emergently, in-
hospital mortality was signiﬁcantly lower with TEVAR than
open surgery (10.8% versus 17.5%, P = .045). This ﬁnding
is consistent with other reports in the literature. In patients
with complicated TBAD, Zeeshan et al. [14] demonstrated
signiﬁcantly lower 30-day mortality (4% versus 40%; P
= .006) among TEVAR recipients (n = 45) compared to open
repair recipients (n = 20). Also, in patients with complicated
TBAD, International Registry of Acute Aortic Dissection
(IRAD) investigators demonstrated signiﬁcantly lower in-
hospital mortality among TEVAR recipients (10.6% versus
33.9%, P = .002) as well as lower rates of stroke and acute
renal failure (20.8% versus 40.0%, P = .04) [6]. In a recentInternational Journal of Vascular Medicine 5
Table 3: Baseline characteristics of electively admitted patients undergoing open surgical repair or TEVAR for type B dissections from 2005
to 2008.
Variable Unmatched cohort Matched cohort
Open repair
(n = 680)
TEVAR
(n = 567)
P value Open repair
(n = 282)
TEVAR
(n = 282)
P value
Mean or % of patients Mean or % of patients
Female sex 29.5 25.9 0.520 32.0 26.6 0.531
Age
Mean age (years) 58.3 63.0 0.008 60.7 62.0 0.485
<60 yr 50.4 37.2 0.040 46.1 44.3 0.842
60–64 yr 12.2 14.0 0.637 11.8 11.9 0.992
65–69 yr 11.9 14.7 0.548 10.8 12.4 0.822
70–74 yr 11.0 19.1 0.080 15.9 17.5 0.822
75–79 yr 10.2 11.0 0.852 8.6 8.7 0.978
≥80 yr 4.3 4.1 0.943 6.9 5.3 0.758
Hospital bed size
Small 4.4 17.3 0.022 7.9 9.3 0.739
Medium 18.5 16.1 0.743 19.5 19.9 0.970
Large 77.1 66.6 0.278 72.6 70.8 0.863
Teaching hospital 79.6 75.4 0.632 79.1 85.7 0.483
Mean annual TEVAR volume (n) 9.3 28.5 <0.001 14.1 14.7 0.656
Comorbid conditions
Cardiac comorbidities 53.1 39.6 0.048 42.2 37.5 0.635
Cardiac arrhythmia 18.8 17.0 0.700 23.1 16.6 0.323
Chronic CHF∗ 11.1 10.2 0.828 12.2 11.9 0.973
Coronary disease 16.2 23.1 0.233 15.9 16.7 0.916
Valvular disease 27.9 7.3 <0.001 8.3 11.8 0.504
Chronic pulmonary disease 18.2 23.6 0.309 19.5 24.4 0.496
Chronic renal failure 12.7 11.4 0.754 10.5 15.5 0.445
Coagulopathy 15.7 3.7 0.004 3.5 5.1 0.681
Deﬁciency anemias 10.2 8.4 0.632 10.5 12.0 0.801
Diabetes 9.8 19.6 0.030 10.7 14.0 0.554
Hypertension 65.4 85.0 <0.001 72.0 76.0 0.600
Obesity 8.3 13.9 0.129 11.0 8.6 0.690
Other neurological disorders 4.4 3.8 0.793 1.9 3.9 0.566
Paralysis 3.0 0.9 0.269 1.7 1.8 0.967
Peripheral vascular disease 19.7 27.6 0.131 21.3 27.7 0.409
∗CHF: congestive heart failure.
meta-analysis of TEVAR use in complicated acute type B
dissections, Luebke and Brunkwall [15] reported an in-
hospital mortality rate of 11.5%.
In contrast to what we observed with emergently admit-
ted patients, TEVAR did not appear to have an impact on the
mortalityofnonemergentTBADpatients(3.3%versus5.6%,
P = .464). However, the more relevant question for patients
with uncomplicated type B aortic dissection is how the out-
comes of TEVAR compare to medical therapy, the standard
of care for this disease. Unfortunately, our study could not
address this question as large datasets like the NIS do not
contain anatomical information about the disease, which
wouldbeneededtodistinguishtypeAandtypeBdissections.
Our ability to make this distinction in surgical patients relied
on the coding of associated aortic arch and aortic valve pro-
cedures,commonlyrequiredtorepairtypeAdissections.Itis
clear that comparing the outcomes of medical therapy to
TEVARforuncomplicatedtypeBdissectionswillrequirepri-
mary data collection, preferably in the form of a randomized
controlled trial.
In looking at the relationship between TEVAR volume
and outcome of treatment in emergently treated TBAD
patients, we observed over a fourfold diﬀerence in mortality
(13.4% versus 2.9%) between the lowest volume group (1–4
TEVARprocedures/year)andthehighestvolumegroup(over
55TEVARprocedures/year).Hospitalsthatperformlessthan6 International Journal of Vascular Medicine
Table 4: In-hospital outcomes after open repair or TEVAR in a
matched cohort of emergently admitted patients.
Open repair
(n = 991)
TEVAR
(n = 991)
P value
mean or % of patients
Mortality 17.5 10.8 0.045
Acute renal failure 27.3 16.8 0.008
Cardiac complications 16.6 8.9 0.029
Neurological complications 11.0 9.3 0.561
Paraplegia 2.5 3.2 0.705
Posthemorrhagic anemia 22.6 12.1 0.006
Postoperative hemorrhage 13.5 9.2 0.209
Pulmonary complications 34.4 24.9 0.052
Stroke 6.2 3.7 0.239
Thrombectomy or
embolectomy 1.9 5.0 0.133
Mean length of stay (days) 15.0 13.9 0.832
Table 5: In-hospital outcomes after open repair or TEVAR in a
matched cohort of electively admitted patients.
Open repair
(n = 282)
TEVAR
(n = 282)
P value
mean or % of patients
Mortality 5.6 3.3 0.464
Acute renal failure 13.0 1.7 0.021
Cardiac complications 15.8 3.6 0.021
Neurological complications 1.9 5.4 0.348
Paraplegia 0.0 0.0
Posthemorrhagic anemia 17.3 3.5 0.017
Postoperative hemorrhage 19.1 5.2 0.009
Pulmonary complications 35.0 16.2 0.034
Stroke 1.9 3.6 0.600
Thrombectomy or
embolectomy 1.8 7.3 0.171
Mean length of stay (days) 11.3 7.7 0.205
thirty TEVAR procedures annually had more than twofold
higher in-hospital mortality for emergent TBAD patients
than hospitals performing more than 30 TEVAR procedures
a year (11.3% versus 4.8%, P = .047). Although this analysis
did not adjust for diﬀerences between the volume groups,
which would have required a larger sample size, our
restricting the analysis to the subgroup who was hospitalized
emergently does help to minimize the diﬀerences between
the volume groups. Our ﬁnding is consistent with others. In
a meta-analysis of 609 patients undergoing TEVAR for aortic
dissection (96% TBAD), Eggebrecht et al. [5]c o n c l u d e d
that surgeons’ experience with TEVAR inﬂuenced outcomes
because hospitals that performed more than twenty TEVAR
procedures had signiﬁcantly lower 30-day mortality than
hospitals with less than twenty procedures (3.2% versus
8.5%; P < .001).
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Figure 1: In-hospital mortality rates for emergently admitted
TBAD patients undergoing TEVAR based on the annual hospital
volume of TEVAR procedures performed. The following are the
number of emergently admitted TBAD patients treated with
endovascular repair in each TEVAR volume group: 1–4 (n = 225),
5–8 (n = 237), 9–14 (n = 217), 15–29 (n = 239), 30–55 (n = 241),
greater than 55 (n = 167), less than 30 (n = 917), 30 or more (n =
408).
One limitation of our study is that it is observational
and carries all the potential biases inherent to such studies.
For instance, the subgroups of patients who underwent
TEVAR and open repair diﬀered substantially (Tables 2 and
3). We adjusted our comparisons for such diﬀerences by
comparing propensity score-matched cohorts; however, it is
possible that there is still some bias in the analyzed cohorts
due to confounders that were not recognized. Furthermore,
the comorbidity data, which was the basis for the com-
parisons between treatment groups, was originally collected
for administrative purposes and subject to coding errors.
Another important limitation to our study is that it does
not address long-term outcomes. Complications unique to
treatment with TEVAR, such as endoleak, graft migration,
and retrograde type A dissection, can contribute to mortality
and complications after a patient is discharged from the
hospital [16, 17]. Longitudinal analysis in the form of
randomized controlled clinical trials is needed in order
to determine the long-term outcomes of TEVAR used for
type B dissections and to ascertain whether favorable in-
hospital outcomes for TEVAR in emergently admitted TBAD
patients persist over time. The recent INSTEAD trial was
the ﬁrst prospective, randomized, and controlled compar-
ison of TEVAR and medical treatment in uncomplicated
TBAD, and it showed that there was no diﬀerence in one-
year mortality between TEVAR and medical therapy alone,
despite signiﬁcantly greater aortic remodeling in TEVAR
[18]. However, INSTEAD was not appropriately powered to
ﬁnd a diﬀerence with the high survival rates they observed
in the medical therapy group. Moreover, INSTEAD did
not restrict enrollment to current deﬁnitions of acute
uncomplicated TBAD, which many believe is the subgroup
with greatest chance of showing a beneﬁt to TEVAR [8].
Manyoftheselimitations arebeingaddressedbytheongoing
ADSORB clinical trial [19].International Journal of Vascular Medicine 7
5. Conclusions
Our study demonstrates that endovascular repair is becom-
ing an important treatment modality for type B dissection.
Approximately 31.5% of the surgical repairs of TBAD in
the United States are performed using this modality. Our
analysis of the NIS dataset, using propensity score matching,
demonstrated that TEVAR outperforms open surgery among
emergently admitted patients with type B aortic dissection,
both in terms of in-hospital mortality and morbidity. This
was not the case for electively admitted patients, where
TEVAR appeared to impart a short-term morbidity beneﬁt
only. We observed a signiﬁcant volume outcome relationship
between overall TEVAR use and in-hospital mortality rates,
which, if conﬁrmed through additional studies, should guide
institutional targets for optimal outcomes of therapy.
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